Pre-treatment [ 18 F]FDG PET/CT for assessing bone marrow involvement and prognosis in patients with newly diagnosed peripheral T-cell lymphoma

• Published in: Hematology (Luxembourg) 2024-12, Vol.29 (1), p.2325317-2325317
• Main Authors: Chen, Jing, Zhao, Yi
• Format: Article
• Language: English
• Subjects: Biopsy; Bone Marrow - diagnostic imaging; Bone Marrow - pathology; Fluorodeoxyglucose F18; Humans; Lymphoma, T-Cell, Peripheral - diagnostic imaging; Lymphoma, T-Cell, Peripheral - therapy; Positron Emission Tomography Computed Tomography - methods; Positron emission tomography/computerized tomography; bone marrow biopsy; bone marrow involvement; peripheral t-cell lymphomas; Positron-Emission Tomography - methods; Prognosis; Retrospective Studies
• ISSN: 1607-8454; 1607-8454
• DOI: 10.1080/16078454.2024.2325317

To explore the value of [ F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in assessing bone marrow involvement (BMI) and prognosis in newly diagnosed peripheral T-cell lymphomas (PTCLs) before treatment. This retrospective study included 201 eligible PTCLs who received pre-bone marrow biopsy (BMB) and PET/CT. The status of bone marrow (BM) by PET was assessed using a visual examination and a quantitative index (the maximal standardized uptake value [SUV ] of BM divided by the SUV of the liver [M/L]). Totally 148 patients had no evidence of BMI by PET or BMB; BMI was detected by both methods in 16 patients. The sensitivity and specificity of PET/CT for patients with confirmed BMI by BMB were 43.2% and 90.2%, respectively (κ =  0.353). In addition, 25 patients assessed by PET/CT staging (having stage I to II disease) had no evidence of BMI detected by both PET/CT and BMB. Image-guided biopsy was also recommended when PET/CT showed a focal FDG uptake outside the iliac crest. Survival analysis revealed that BMB was significant for overall survival (OS) (  = 0.020) while M/L for both progression free survival (  = 0.002) and OS (